Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target

Reuters

2025/12/05

Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target

Emerging Growth Research has released a flash report on OSR Holdings Inc. $(OSRH)$, reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276983) on December 04, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2589783230"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589783230\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589783230?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589783230","market":"fut","top_or_hot":-1,"title":"Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emerging Growth Research has released a flash report on OSR Holdings Inc. <a href=\"https://laohu8.com/S/OSRH\">$(OSRH)$</a>, reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276983) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-05 04:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emerging Growth Research has released a flash report on OSR Holdings Inc. <a href=\"https://laohu8.com/S/OSRH\">$(OSRH)$</a>, reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276983) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4SmJC2:1","article_id":"2589783230","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589783230","pubTimestamp":1764879594,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Emerging Growth Research has released a flash report on OSR Holdings Inc. , reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OSRH":"OSR Holdings"},"translate_title":"Emerging Growth Research重申买入OSR Holdings，目标价10美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSRH":0.9},"content_text":"Emerging Growth Research Reaffirms Buy on OSR Holdings With $10 Price Target\n    \n\n        Emerging Growth Research has released a flash report on OSR Holdings Inc. $(OSRH)$, reaffirming its Buy-Emerging rating and setting a 12-month price target of $10.00, representing a potential 1,487% upside from the company's recent closing price. The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at $815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01. The agreement, which includes an expected $20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276983) on December 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}